NOT FOR DISTRIBUTION
Header cover image

Tonghua Dongbao Pharmaceutical

Market Cap

CN¥24.6b

Last Updated

2021/04/17 09:04 UTC

Data Sources

Company Financials +

Executive Summary

Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products for the treatment of diabetes and cardiovascular-based diseases in China. More Details


Snowflake Analysis

Flawless balance sheet with solid track record.

Share Price & News

How has Tonghua Dongbao Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 600867 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 600867's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

0.7%

600867

-2.8%

CN Pharmaceuticals

-0.8%

CN Market


1 Year Return

2.1%

600867

10.4%

CN Pharmaceuticals

25.0%

CN Market

Return vs Industry: 600867 underperformed the CN Pharmaceuticals industry which returned 10.4% over the past year.

Return vs Market: 600867 underperformed the CN Market which returned 25% over the past year.


Shareholder returns

600867IndustryMarket
7 Day0.7%-2.8%-0.8%
30 Day-3.6%1.0%-0.08%
90 Day-1.1%-5.1%-5.3%
1 Year3.5%2.1%11.5%10.4%27.0%25.0%
3 Year-40.1%-42.1%25.2%20.8%29.1%22.8%
5 Year-9.4%-14.0%46.5%38.7%30.5%21.7%

Long-Term Price Volatility Vs. Market

How volatile is Tonghua Dongbao Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Tonghua Dongbao Pharmaceutical undervalued compared to its fair value and its price relative to the market?

26.48x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 600867 (CN¥12.18) is trading above our estimate of fair value (CN¥8.02)

Significantly Below Fair Value: 600867 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 600867 is good value based on its PE Ratio (26.5x) compared to the CN Pharmaceuticals industry average (31.9x).

PE vs Market: 600867 is good value based on its PE Ratio (26.5x) compared to the CN market (33.6x).


Price to Earnings Growth Ratio

PEG Ratio: 600867 is poor value based on its PEG Ratio (1.5x)


Price to Book Ratio

PB vs Industry: 600867 is overvalued based on its PB Ratio (4.7x) compared to the CN Pharmaceuticals industry average (2.7x).


Future Growth

How is Tonghua Dongbao Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

17.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600867's forecast earnings growth (17.3% per year) is above the savings rate (3.3%).

Earnings vs Market: 600867's earnings (17.3% per year) are forecast to grow slower than the CN market (22.9% per year).

High Growth Earnings: 600867's earnings are forecast to grow, but not significantly.

Revenue vs Market: 600867's revenue (16.1% per year) is forecast to grow slower than the CN market (17.7% per year).

High Growth Revenue: 600867's revenue (16.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 600867's Return on Equity is forecast to be high in 3 years time (23.2%)


Past Performance

How has Tonghua Dongbao Pharmaceutical performed over the past 5 years?

9.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 600867 has high quality earnings.

Growing Profit Margin: 600867's current net profit margins (32.2%) are higher than last year (29.2%).


Past Earnings Growth Analysis

Earnings Trend: 600867's earnings have grown by 9% per year over the past 5 years.

Accelerating Growth: 600867's earnings growth over the past year (14.6%) exceeds its 5-year average (9% per year).

Earnings vs Industry: 600867 earnings growth over the past year (14.6%) exceeded the Pharmaceuticals industry 10.3%.


Return on Equity

High ROE: 600867's Return on Equity (17.6%) is considered low.


Financial Health

How is Tonghua Dongbao Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: 600867's short term assets (CN¥1.8B) exceed its short term liabilities (CN¥129.0M).

Long Term Liabilities: 600867's short term assets (CN¥1.8B) exceed its long term liabilities (CN¥77.2M).


Debt to Equity History and Analysis

Debt Level: 600867 is debt free.

Reducing Debt: 600867 has no debt compared to 5 years ago when its debt to equity ratio was 36.9%.

Debt Coverage: 600867 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 600867 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Tonghua Dongbao Pharmaceutical current dividend yield, its reliability and sustainability?

1.64%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 600867's dividend (1.64%) is higher than the bottom 25% of dividend payers in the CN market (0.44%).

High Dividend: 600867's dividend (1.64%) is low compared to the top 25% of dividend payers in the CN market (1.79%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 600867 has been paying a dividend for less than 10 years.

Growing Dividend: 600867's dividend payments have increased, but the company has only paid a dividend for 9 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (43.5%), 600867's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: 600867's dividends in 3 years are forecast to be well covered by earnings (32.7% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.1yrs

Average management tenure


CEO

Sheng Leng Chun (46 yo)

no data

Tenure

CN¥1,173,200

Compensation

Mr. Chun Sheng Leng is the Chairman and General Manager at Tonghua Dongbao Pharmaceutical Co., Ltd. and served as its Deputy General Manager since March 27, 2014. and has been its Director since March 27, ...


Leadership Team

Experienced Management: 600867's management team is seasoned and experienced (7.1 years average tenure).


Board Members

Experienced Board: 600867's board of directors are considered experienced (7.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Tonghua Dongbao Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Ticker: 600867
  • Exchange: SHSE
  • Founded: 1985
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥24.623b
  • Shares outstanding: 2.02b
  • Website: https://www.thdb.com

Number of Employees


Location

  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Dongbao New Village
  • Tonghua County
  • Tonghua
  • Jilin Province
  • 134123
  • China

Listings


Biography

Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products for the treatment of diabetes and cardiovascular-based diseases in China. The company opera...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/17 09:04
End of Day Share Price2021/04/16 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.